Tirzepatide can be a difficult subject to enter halfway through a conversation. There are several product names, different reasons for prescribing it, and plenty of advertising that leaves out the distinctions.
Start with three separate questions: What medicine is this? What is the clinician treating? Which exact product would you receive? Keeping those questions apart makes the rest of the research easier.
An ingredient name tells you less than the complete prescription: product, purpose, formulation, and follow-up all matter.
One ingredient, different treatment purposes
Tirzepatide acts at two hormone receptors, GIP and GLP-1. Its effects include changes in appetite and blood-sugar regulation. That mechanism helps explain its uses; it does not establish that it is suitable for every person who wants to lose weight.
Zepbound is an approved tirzepatide product for specified adult weight-management use and for moderate-to-severe obstructive sleep apnea in adults with obesity. Mounjaro has a different label, including type 2 diabetes treatment. Our Zepbound and Mounjaro comparison walks through those distinctions.
Sources: Lilly: Zepbound prescribing information · Lilly: Mounjaro prescribing information
A brand name is not the whole treatment plan
An appointment should connect the proposed medicine to your health history, current medicines, goals, and ability to manage treatment over time. A question about appetite is different from a question about diabetes, and both deserve more than a checkout selection.
Bring your medication list and any previous treatment experience. Include medicines you have stopped and why you stopped them. A clinician can use that history to discuss alternatives and decide whether an assessment or additional records are needed. The first-appointment guide helps organize that conversation.
Sources: NIDDK: Prescription medicines for overweight and obesity · FDA: Managing medicine benefits and risks
Compounded products require a separate discussion
A compounded tirzepatide prescription is not FDA-approved Zepbound or Mounjaro. FDA does not review compounded drugs for safety, effectiveness, and quality before marketing. The end of the tirzepatide shortage also matters to the rules around making copies of commercially available drugs.
If a service offers a compounded product, ask why an approved option would not meet your medical needs, what formulation is proposed, and which pharmacy will dispense it. A lower advertised price alone does not settle those questions. Read the compounding fieldnote before comparing checkout offers.
Sources: FDA: Concerns with unapproved GLP-1 drugs · FDA: GLP-1 supply and compounding policy · FDA: Compounding questions and answers
Leave with a next step you can explain
A useful first discussion ends with a plan you understand: whether treatment is appropriate, what product is being considered, what it costs, and how questions or side effects will be handled. You should know how to reach the clinical team rather than relying on a general sales inbox.
The visit notebook gives you a short set of questions to copy or print. Take your time with the answers. A service being easy to join does not tell you whether its treatment is right for you.
Sources: FDA: Managing medicine benefits and risks · FDA: Buying medicines from online pharmacies
The source shelf
- Lilly: Zepbound prescribing information
Current approved-product label, revised August 2026; does not establish equivalence of compounded preparations.
- Lilly: Mounjaro prescribing information
Product-specific diabetes indications and safety information. Not an interchangeable label for compounded tirzepatide.
- NIDDK: Prescription medicines for overweight and obesity
Chronic weight-management decisions and ongoing lifestyle care.
- FDA: Managing medicine benefits and risks
General questions for clinical decision-making and medication follow-up.
- FDA: Concerns with unapproved GLP-1 drugs
Compounding, fraudulent labels, dosing errors and the limits of adverse-event reports. Checked September 23, 2026.
- FDA: GLP-1 supply and compounding policy
Shortage resolution and restrictions on essentially copies; availability requires current professional assessment.
- FDA: Compounding questions and answers
Compounded medicines do not undergo FDA premarket review like approved drugs.
- FDA: Buying medicines from online pharmacies
Checks for prescription requirements, licensing, contact details and pharmacy support.
